UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $194.76 and last traded at $194.76, with a volume of 0 shares traded. The stock had previously closed at $194.76.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm’s fifty day moving average price is $181.53 and its 200-day moving average price is $157.20.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Where to Find Earnings Call Transcripts
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What is the S&P/TSX Index?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
